Target intelligence / Profile preview

White adipose tissue to brown adipose tissue transdifferentiation pathway

Molecular classification
Other (biological process/pathway)
01

Overview

The "White adipose tissue to brown adipose tissue transdifferentiation pathway" refers to the biological process by which mature white fat cells acquire characteristics of brown fat cells—a phenomenon often called "browning" or "beiging." White adipocytes primarily store energy as large lipid droplets, while brown adipocytes specialize in burning lipids for heat production through adaptive thermogenesis. This transformation is marked by increased mitochondrial content and upregulation of genes such as UCP1 that drive uncoupled respiration. The process is reversible and can be triggered by cold exposure, certain hormones, or pharmacologic agents like β3-adrenoceptor agonists. Browning has attracted significant interest due to its potential role in combating obesity and related metabolic disorders by increasing energy expenditure. However, this entry describes a cellular differentiation pathway rather than a discrete molecular target such as a receptor or enzyme; thus it is not itself considered a therapeutic target but rather an important biological mechanism involving multiple targets including receptors like the β3-adrenoceptor.[1][2][5]

Other names
WAT to BAT transdifferentiation pathwayBrowning of white adipose tissueWhite-to-brown fat conversionAdipocyte plasticity pathway
02

Mechanism of action

Activation of β3-adrenoceptors stimulates the conversion of white to brown/brite adipocytes, increasing thermogenic gene expression and energy expenditure[2].

03

Biological functions

Energy metabolism regulationThermogenesisAdipocyte differentiation and plasticity
04

Disease associations

ObesityMetabolic syndromeType 2 diabetes (indirectly, via metabolic effects)Cardiovascular disease (indirectly, via metabolic effects)
05

Safety considerations

Off-target adrenergic stimulation with β3 agonists may cause cardiovascular side effects in humans[2].Long-term safety and efficacy for browning agents are not fully established.
06

Interacting drugs

β3-adrenoceptor agonists (e.g., mirabegron in research context)[2]

1 more in the full profile.

07

Biomarkers

UCP1 expression (uncoupling protein 1)[1]CIDEA[1]PGC‐1α[1]

Beyond the preview

Go deeper on White adipose tissue to brown adipose tissue transdifferentiation pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on White adipose tissue to brown adipose tissue transdifferentiation pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call